Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions.

Magaret A, Dong L, John M, Mallal SA, James I, Warren T, Gaudieri S, Koelle DM, Wald A.

Genes Immun. 2016 Dec;17(7):412-418. doi: 10.1038/gene.2016.42.

PMID:
27853144
2.

In vivo disruption of latent HSV by designer endonuclease therapy.

Aubert M, Madden EA, Loprieno M, DeSilva Feelixge HS, Stensland L, Huang ML, Greninger AL, Roychoudhury P, Niyonzima N, Nguyen T, Magaret A, Galleto R, Stone D, Jerome KR.

JCI Insight. 2016 Sep 8;1(14). pii: e88468.

3.

Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.

Schiffer JT, Swan DA, Magaret A, Schacker TW, Wald A, Corey L.

PLoS One. 2016 Jun 10;11(6):e0155124. doi: 10.1371/journal.pone.0155124.

4.

Viral Spread to Enteric Neurons Links Genital HSV-1 Infection to Toxic Megacolon and Lethality.

Khoury-Hanold W, Yordy B, Kong P, Kong Y, Ge W, Szigeti-Buck K, Ralevski A, Horvath TL, Iwasaki A.

Cell Host Microbe. 2016 Jun 8;19(6):788-99. doi: 10.1016/j.chom.2016.05.008.

PMID:
27281569
5.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.

Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.

Sci Transl Med. 2016 Feb 3;8(324):324ra15. doi: 10.1126/scitranslmed.aad6654.

6.

Serological and biomolecular survey on canine herpesvirus-1 infection in a dog breeding kennel.

Bottinelli M, Rampacci E, Stefanetti V, Marenzoni ML, Malmlov AM, Coletti M, Passamonti F.

J Vet Med Sci. 2016 Jun 1;78(5):797-802. doi: 10.1292/jvms.15-0543.

7.

Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Johnston C, Corey L.

Clin Microbiol Rev. 2016 Jan;29(1):149-61. doi: 10.1128/CMR.00043-15. Review.

8.

Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda.

Phipps W, Nakku-Joloba E, Krantz EM, Selke S, Huang ML, Kambugu F, Orem J, Casper C, Corey L, Wald A.

J Infect Dis. 2016 Feb 1;213(3):439-47. doi: 10.1093/infdis/jiv451.

PMID:
26486633
9.

Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living With HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study.

Low AJ, Nagot N, Weiss HA, Konate I, Kania D, Segondy M, Meda N, van de Perre P, Mayaud P; Yerelon Study Group..

J Infect Dis. 2016 Mar 1;213(5):731-7. doi: 10.1093/infdis/jiv495.

10.
11.

Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.

BenMohamed L, Osorio N, Srivastava R, Khan AA, Simpson JL, Wechsler SL.

J Neurovirol. 2015 Oct;21(5):508-17. doi: 10.1007/s13365-015-0348-9.

12.

Comparable mRNA expression of inflammatory markers but lower claudin-1 mRNA levels in foreskin tissue of HSV-2 seropositive versus seronegative asymptomatic Kenyan young men.

Röhl M, Tjernlund A, Mehta SD, Pettersson P, Bailey RC, Broliden K.

BMJ Open. 2015 Feb 18;5(2):e006627. doi: 10.1136/bmjopen-2014-006627.

13.

Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

Tan DH, Raboud JM, Szadkowski L, Yi TJ, Shannon B, Kaul R, Liles WC, Walmsley SL.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):276-81. doi: 10.1089/AID.2014.0183.

14.

Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.

Dhankani V, Kutz JN, Schiffer JT.

PLoS Comput Biol. 2014 Nov 6;10(11):e1003922. doi: 10.1371/journal.pcbi.1003922.

15.

Prevalence and factors associated with herpes simplex virus type 2 infection in patients attending a Baltimore City emergency department.

Patel EU, Frank MA, Hsieh YH, Rothman RE, Baker AE, Kraus CK, Shahan J, Gaydos CA, Kelen GD, Quinn TC, Laeyendecker O.

PLoS One. 2014 Jul 18;9(7):e102422. doi: 10.1371/journal.pone.0102422.

16.

Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences.

Mark KE, Spruance S, Kinghorn GR, Sacks SL, Slade HB, Meng TC, Selke S, Magaret A, Wald A.

Antimicrob Agents Chemother. 2014 Sep;58(9):5016-23. doi: 10.1128/AAC.00077-14.

17.

Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, Corey L.

J Virol. 2014 May;88(9):4921-31. doi: 10.1128/JVI.03285-13.

18.

Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.

J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13.

19.

Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Tan DH, Murphy K, Shah P, Walmsley SL.

BMC Infect Dis. 2013 Oct 28;13:502. doi: 10.1186/1471-2334-13-502. Review.

20.

Pathogenesis and current approaches to control of varicella-zoster virus infections.

Gershon AA, Gershon MD.

Clin Microbiol Rev. 2013 Oct;26(4):728-43. doi: 10.1128/CMR.00052-13. Review.

Items per page

Supplemental Content

Support Center